021-51111890
购物车（）
sales@molnova.cn
Letolizumab
CAS No. 1450981-87-9
Letolizumab ( —— )
产品货号. M36807 CAS No. 1450981-87-9
Letolizumab (BMS-986004) 是一种靶向 CD40L 的单克隆抗体，其产生是为了表达缺乏效应器功能的突变 IgG1，包括 Fc 结合和补体固定。Letolizumab 降低了排斥反应、血栓栓塞，延长了存活时间。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥4902 | 有现货 |
|
| 10MG | ￥6603 | 有现货 |
|
| 25MG | ￥9765 | 有现货 |
|
| 50MG | ￥13206 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Letolizumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Letolizumab (BMS-986004) 是一种靶向 CD40L 的单克隆抗体，其产生是为了表达缺乏效应器功能的突变 IgG1，包括 Fc 结合和补体固定。Letolizumab 降低了排斥反应、血栓栓塞，延长了存活时间。
-
产品描述Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.
-
体外实验——
-
体内实验Animal Model:Rhesus macaques after renal transplantation.Dosage:2, 10 and 20 mg/kg.Administration:Intravenous injection; once a week for 10 weeks.Result:Increased the survival time.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Immunology/Inflammation related
-
研究领域——
-
适应症——
化学信息
-
CAS Number1450981-87-9
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Karnell JL, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2019 Feb 15;141:92-103. ?
产品手册
关联产品
-
2-Amino-3-carboxy-1,...
2-Amino-3-carboxy-1,4-naphthoquinone is the electron transfer mediator, can change glucose metabolism of the homofermentative lactic acid bacteria.
-
[Ala1,?3,?11,?15]?-?...
[Ala1,3,11,15]-Endothelin (TFA) is a highly selective for endothelin A (ETA) and endothelin B (ETB) receptor.[Ala1,?3,?11,?15]?-?Endothelin is a selective ETB endothelin receptor agonist (IC50 values are 0.33 and 2200 nM for displacing [125I]-ET-1 from ETB and ETA receptors respectively).
-
Triethyl citrate
柠檬酸三乙酯用于药物涂层和塑料。
